WO2003027233A2 - Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon - Google Patents
Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon Download PDFInfo
- Publication number
- WO2003027233A2 WO2003027233A2 PCT/US2002/029256 US0229256W WO03027233A2 WO 2003027233 A2 WO2003027233 A2 WO 2003027233A2 US 0229256 W US0229256 W US 0229256W WO 03027233 A2 WO03027233 A2 WO 03027233A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microorganism
- microorganisms
- growth
- support medium
- chamber
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 193
- 238000002955 isolation Methods 0.000 title abstract description 10
- 238000007876 drug discovery Methods 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 105
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- 238000009792 diffusion process Methods 0.000 claims abstract description 27
- 238000003501 co-culture Methods 0.000 claims abstract description 13
- 230000012010 growth Effects 0.000 claims description 129
- 239000002609 medium Substances 0.000 claims description 70
- 235000015097 nutrients Nutrition 0.000 claims description 47
- 229920001817 Agar Polymers 0.000 claims description 45
- 239000008272 agar Substances 0.000 claims description 45
- 239000013049 sediment Substances 0.000 claims description 37
- 239000012528 membrane Substances 0.000 claims description 34
- 239000002054 inoculum Substances 0.000 claims description 28
- 239000013535 sea water Substances 0.000 claims description 21
- 230000007613 environmental effect Effects 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 13
- 101100078001 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MSC2 gene Proteins 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000002689 soil Substances 0.000 claims description 10
- 230000011664 signaling Effects 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 239000004576 sand Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 239000013505 freshwater Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 3
- 239000003471 mutagenic agent Substances 0.000 claims description 3
- 231100000707 mutagenic chemical Toxicity 0.000 claims description 3
- 230000003505 mutagenic effect Effects 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 1
- 238000000151 deposition Methods 0.000 claims 1
- 238000009509 drug development Methods 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000000813 microbial effect Effects 0.000 description 21
- 239000000463 material Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000011534 incubation Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000005018 casein Substances 0.000 description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 6
- 235000021240 caseins Nutrition 0.000 description 6
- 239000006325 marine broth Substances 0.000 description 6
- 239000004417 polycarbonate Substances 0.000 description 6
- 229920000515 polycarbonate Polymers 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 150000002611 lead compounds Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000565 sealant Substances 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 241001210413 Lewinella persica Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003016 pheromone Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000007320 rich medium Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 4
- 239000002028 Biomass Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000010256 biochemical assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 101150117600 msc1 gene Proteins 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000863029 Herpetosiphon Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000001152 differential interference contrast microscopy Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- -1 e.g. Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000012203 high throughput assay Methods 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000018612 quorum sensing Effects 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241001135163 Arcobacter Species 0.000 description 1
- 241001135166 Arcobacter nitrofigilis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001148568 Epsilonproteobacteria Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001210401 Lewinella Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108091077107 LuxS family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000230565 Sphingobacteriia Species 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241001123263 Zostera Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000001317 epifluorescence microscopy Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 244000000000 soil microbiome Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011351 state-of-the-art imaging technique Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Definitions
- the method of the invention is directed to the novel use of a diffusion chamber as a growth chamber within which previously "uncultivatible" microorganisms can be isolated. Rather than attempting to replicate the natural environment of an unknown microorganism on a Petri dish, the method of the invention provides for exposing dividing microorganisms to all of the contents of the original environment while simultaneously providing a growth site for the microorganisms and containing the resulting colonies so that they can be isolated.
- microorganisms include but are not limited to bacteria, fungi, protozoa, viruses and icroalgae.
- the method of the invention preferably takes advantage of the recognition that, in some environments, the preponderance of difficult-to-grow microorganisms do not form colonies visible to the naked eye. Therefore, these organisms must be isolated under a compound microscope as "microcolonies . " Finally, some of the newly isolated organisms have been discovered to be capable of growing in artificial media as a co-culture in the presence of a companion, or "helper, " organism. A novel way of isolating and identifying novel organisms using such helper organisms has been developed.
- the invention is directed to a novel method for isolating and cultivating microorganisms from an environmental sample, the method including the steps of providing a sample from an environment to be tested; providing a growth chamber, which when sealed, preferably with a semi- permeable membrane, is permeable to diffusion of components from the environment but not to cells of microorganisms; mixing an inoculum from the sample with a support medium, preferably se i- solid, e.g., 0.7% agar, inside the growth chamber and sealing the chamber; incubating the sealed chamber under growth conditions in which components from the environment diffuse into the chamber and growth of microorganisms occurs; opening the chamber and examining the support medium inside the chamber for the presence of, e.g., surface or indwelling colonies of microorganisms; and isolating cells from one of the colonies.
- the characteristics of the newly isolated cells can be compared with a database of characteristics of known microorganisms to determine novelty.
- the support medium preferably is examined micro
- sampling sites include specific areas in a building, e.g., a hospital, with samples being taken from a site such as the ventilation system, bathroom wall surface or hospital room surface.
- the invention is directed to a method for isolating a novel microorganism from marine sediment, the method including the steps of providing a sample of marine sediment; providing a growth chamber sealable by a semi- permeable membrane that is permeable to diffusion of growth components but is not permeable to cells of microorganisms; mixing an inoculum from the sample with a semi-solid support medium, e.g., 0.7% agar, inside the growth chamber; sealing the chamber with the semi-permeable membrane while leaving an airspace between the surface of the support medium and the membrane; incubating the sealed chamber in a marine environment wherein seawater from the environment displaces the air in the airspace, thus filling the growth chamber, and growth components from the environment diffuse into the chamber and allow growth of microorganisms; removing the chamber from the marine environment, peeling off the membrane and examining the support medium microscopically for the presence of surface or indwelling microcolonies of microorganisms; isolating cells from one of the
- the growth chamber according to the invention also allows for the diffusion out of waste products.
- the support medium is provided as a soft, e.g., 0.7%, agar.
- the soft agar may be mixed with autoclaved sand or mud.
- novel organisms isolated as described above, have been found to be capable of growing on a standard rich medium in Petri dishes when in co-culture with a "helper" organism.
- novel microorganisms are isolated that are capable of growing in artificial media only in the presence of a "helper” organism.
- samples as above from the natural environment are serially diluted in an appropriate medium (e.g., sea water for marine microorganisms and fresh or rainwater for freshwater or soil microorganisms) .
- an appropriate medium e.g., sea water for marine microorganisms and fresh or rainwater for freshwater or soil microorganisms
- helper identified as described below
- Petri dishes (2 to 10 ml per dish) .
- Different Petri dishes will receive various numbers of microorganisms according to the degree of sample dilution and an invariable, low number of "helper” cells (e.g., 10-100 cells per dish) .
- the "helper” cells will enable growth in Petri dishes of certain of the microorganisms, which growth will be detected visually as clusters of colonies surrounding a colony of a helper strain (as in Figs. 5a-5b) . Microorganisms from such a cluster of colonies are tentatively identified as being “uncultivable” when not in the presence of a "helper” organism.
- helper species those that grow in the presence of a helper species but not alone in a Petri dish, even in a nutrient medium, are identified as the sought for organisms, i.e., those organisms previously thought of as “uncultivable, " which are capable of growing in artificial media only in the presence of a "helper” organism.
- the newly identified organism of interest requiring a "helper” organism for growth on a Petri dish, is then tested for bioactivity.
- the growth of those organisms showing positive results for bioactivity can be upscaled by co-culture with a helper organism under conventional in vi tro conditions on an artificial medium, and bioactive compounds can be isolated, many of which will be novel.
- the growth of an organism that grew from a diffusion chamber showing positive results for bioactivity can also be upscaled in pure culture in a number of chambers.
- an extract or supernatant from growing up an "uncultivable'V'helper" combination or a "helper” organism alone can be used as a source of components for growing up new organisms according to the invention.
- the signaling compound (s) responsible for such growth can be isolated.
- Additional "helper" microorganisms from environmental samples can be identified by first isolating into pure culture populations of a number of novel "uncultivable” microorganisms. Representatives of these populations are then serially diluted in an appropriate medium (e.g., sea water in case of marine microorganisms, fresh water in case of freshwater microorganisms), combined in various ratios and mixed with a gel medium (e.g., 0.7% agar) supplemented with standard nutrients
- an appropriate medium e.g., sea water in case of marine microorganisms, fresh water in case of freshwater microorganisms
- a gel medium e.g. 0.7% agar
- the various media containing individual mixtures of microorganisms are poured into Petri dishes and incubated in the laboratory. If the given mixture of cells contains representatives of synergistic partners, the latter will grow in Petri dishes. Because each Petri dish will receive a different number of microorganisms, some of them will exhibit synergistic microbial growth in the form of clusters of colonies. Each microorganism from such microbial clusters is a "helper” to other uncultivable microorganisms and will be used to grow the latter on artificial media. "Helpers" can also be identified from among “cultivable” microorganisms in a similar manner.
- a sample from an environment to be tested is inoculated directly onto a support medium, such as an agar plate, and growth of colonies of microorganisms is observed. Cells from two or more colonies are picked and screened for the ability to grow adjacent to each other on a second plate. Cells from colonies that do grow adjacent to each other are picked and screened for the ability to grow subsequently in separate plates. A novel "uncultivable" microorganism will grow adjacent to a companion but not alone.
- the invention is directed to novel organisms isolated by the methods of the invention. Two specific microorganisms include MSC1 and MSC2, described herein.
- novel isolation methods according to the invention provide a breakthrough for the pharmaceutical industry as they allow for the isolation and cultivation of novel microorganisms with unknown metabolism, life cycle, ecology, etc. Whether or not the factors limiting and/or stimulating growth of these microorganisms are known no longer matters, even though this is a crucial consideration for traditional culturing.
- Novel organisms isolated by the methods of the invention are fertile sources for the isolation and identification of new lead compounds for the development of new therapeutic treatments.
- the invention provides a convenient way to isolate and identify clinically important organisms, some of which may be new, from, e.g., contaminated regions of a medical facility or a "sick" building.
- Fig. la shows an exemplary diffusion growth chamber for in si tu cultivation of marine organisms according to the invention
- Fig. lb shows sealed chambers according to Fig. la placed on the surface of marine sediment in a marine aquarium
- Fig. 2 shows representative colonies of marine sediment microorganisms (compound microscope view, Differential Interference Contrast (DIC) ) grown in growth chambers according to the invention (scale bar, 100 ⁇ m) ;
- DIC Differential Interference Contrast
- Fig. 3 shows growth recovery of microorganisms from environmental samples in the diffusion chambers of Fig. la;
- Figs. 4a-4c show colonies and cells of MSC1 at various magnifications: (4a) Dissecting microscope view of colonies. The bar is 80 ⁇ m. (4b) Compound microscope view of a single colony -
- the bar is 3 ⁇ m.
- the bar is 3 ⁇ m;
- Figs. 5a-5b show synergistic growth on Petri dishes of microorganisms isolated according to the method of the invention, MSC1 and MSC2 (Fig. 5a - dissecting microscope; Fig. 5b - compound microscope) .
- a growth chamber for carrying out the method of the invention is designed to allow for the growth, isolation into pure culture and characterization of microorganisms that are uncultivable at the present time. This desired result can be achieved because the conditions inside the chamber according to the invention closely resemble, if they are not identical to, the natural environment of the microorganisms.
- One version of such a chamber is formed from a solid substrate, e.g., a glass or silicon slide or stainless steel washer, having an orifice which is sandwiched by two robust membranes, e.g., polycarbonate or other inert material, glued onto the substrate.
- the membranes have pore sizes, e.g., 0.025-0.03 ⁇ m, that are sufficiently small to retain all microorganisms inside the chamber but which are sufficiently large to permit components from the environment to diffuse into the chamber and waste products to diffuse out of the chamber.
- the chamber is partially filled with a suspension of test cells in soft agar, e.g., 0.7%.
- the second membrane is used to seal the chamber, leaving an air space between the agar surface and the membrane.
- the inoculum e.g., seawater
- the cells inside are exposed to the same components of the environment, e.g., the same nutrients, growth factors, metabolites of other species, etc., as are their counterparts growing in nature.
- Marine samples have typically been collected from the surface oxygenated areas of a marine sandy tidal flat. Suspensions of cells from the samples are diluted, mixed with warm agar, or similar material that will solidify into a semi- solid support medium, and inoculated into the growth chamber. Some trials can include autoclaved sand and/or mud mixed with semi-solid agar as a solid substrate for those microorganisms that might require such specific surfaces for attachment as a condition for growth. In separate trials, various nutrients and/or electron donors (principally, proteins and polysaccharides) , which might boost the growth rate of uncultivable microorganisms, can be added.
- nutrients and/or electron donors principally, proteins and polysaccharides
- dialysis membranes with, e.g., a 10-20 kD cutoff pore size are placed under the polycarbonate membranes in order to prevent diffusion of the added polymeric nutrients out of the chamber.
- dilutions are prepared over, e.g., three different ranges. For example, initially, dilutions can be prepared such that each chamber receives 1 to 100 "cultivable" cells (determined by plating on marine broth medium) . If the number of colonies appearing in the growth chamber exceeds the number of expected cultivable cells, the growth of (previously) uncultivable microorganisms is indicated.
- the dilution factor can be increased such that each device receives 1 to 100 cells as determined by total microscopy count of DAPI stained cells, or one to three orders of magnitude fewer cells than initially.
- the growth chambers prepared as above are placed in the natural environment, where seawater from the environment replaces the air in the airspace.
- the natural environment may be replicated by, e.g., using a large marine temperature-controlled aquarium containing a 8-10 cm thick layer of field sediment and associated seawater. A larger number of colonies appearing in the growth chamber, exceeding the number of expected cultivable cells, will indicate the growth of
- the growth chambers are opened by simply peeling off the top membrane, which, because of the liquid space that was left between the agar surface and the membrane, does not disturb the surface colonies.
- Each surface and indwelling colony is then inoculated onto a Petri dish with a rich (e.g., marine broth) nutrient medium as well as into a new growth chamber, which will be placed back into the natural environment. This procedure is carried out to look for colonies that fail to grow in a rich medium but do grow in the growth chamber.
- This screen will indicate which of the colonies growing in the growth chamber are potentially from microorganisms previously considered as “uncultivable.”
- Cells from putative "uncultivable" colonies are analyzed by 16S RNA gene sequencing.
- a comparison using, e.g., the online GenBank database (http://ncbi.nlm.nih.gov/GenBank) with known 16S RNA genes will identify the organism and will show whether or not it represents a new species/genus.
- An important feature of growth chamber design is to include membranes that are not targeted as a microbial food source and that are also sufficiently robust to withstand the abrasion action of the sediment fauna and of the sediment itself. Traditional dialysis membranes can serve as a substrate for some microorganisms.
- the sealant used to glue the membranes to the chamber body also has specific requirements.
- the sealant has to last for weeks while being immersed in sea water, and it also must be non-toxic for microorganisms.
- SuperSilicon Type 7 (Versachem Corp.), which is widely used to seal marine aquaria, was successfully used in a number of experiments. This is a very sturdy compound, which holds extremely well under most adverse conditions.
- the growth chambers built with this sealant did not leak for at least several weeks, after which point incubation was stopped. Tests on the sealant' s toxicity proved negative as the sealant exhibited no effect on E. coli growth. This result corroborates well with many earlier findings.
- the nature of the support medium inside the growth chamber is of primary importance to achieving microbial growth.
- This medium should enable microorganisms to divide and form colonies and should also allow the investigator to detect the colonies for subculturing and microbial isolation.
- the medium should be liquid initially at an elevated temperature, or at least sufficiently soft to mix well with an inoculum, and should solidify into a gel at the temperature of incubation.
- suitable media include agar, hydrogels and silica gel.
- a successful basic medium is semi-solid, e.g., 0.7% agar. In its pure form (that is, with no nutrients added), agar is a poor food source and as such is unlikely to provide artificial enrichment for specific microbes.
- agar can be used either alone (in which case microbial growth can be expected solely based on components from the environment diffusing into the chamber from the outside) or in combination with polymers known to promote microbial growth (see below) .
- a support medium useful in the method of the invention also includes an embodiment in which, for ease of handling, an agar/inoculum mixture is processed, e.g., to form a Gel MicroDrop (GMD) matrix (One Cell Systems, Inc., Cambridge, MA, (http://www.onecell.com/gmd.htm)) wherein, in a manner analogous to limited dilution cloning, individual GMDs have a high probability of containing 0 or 1 initial cell, and therefore 0 or 1 microcolony following incubation.
- GMD Gel MicroDrop
- microbes may require specific surfaces for attachment. In the absence of such surfaces, these organisms may be unable to divide and/or form colonies. Therefore, as indicated above, in some trials, e.g., those involving samples from marine sandy tidal flats, sterilized sand is added to the agar. This addition should satisfy the surface requirements of the majority of inoculated microorganisms from this environment.
- microorganisms may have gone unnoticed previously on Petri dishes because they do not form visible colonies.
- Prior work with marine microbes indicates that in sediments, solitary microorganisms are rare and that most microbes form microcolonies on the surface of sand grains and detrital particles. These microcolonies, which are quite small and consist only of a few dozen to several hundred cells, are many times smaller than can be detected under a dissecting microscope. It is likely that, inside the growth chamber, these microorganisms will form microcolonies no larger than they do in the field. Naturally, such colonies will be missed unless they are searched for specifically.
- One method of visualizing these microcolonies is under a compound microscope using vital dyes.
- Nomarski Differential Interference Contrast microscopy is also very useful.
- the cells are contrasted against the background by vital staining/Nomarski microscopy, handling these colonies for subculturing can be challenging. Therefore, appropriate ways to sample and manipulate milligrams of agar and handle very small numbers of cells have been developed.
- a tungsten wire has proven very useful, with or without a micromanipulator to operate it.
- an additional prism in the microscope to compensate for the image inversion that is an almost universal feature of compound microscopes. With this modification, the microscope shows objects with no left-to-right inversion, which greatly facilitates manipulation of the tungsten wire.
- a microscope facility particularly suitable for handling such samples might include, e.g., a Zeiss Axioplan 2 MOT equipped for fluorescence imaging, a Nomarski/DIC microscope, a phase contrast microscope, and a state of the art imaging system (e.g., a Hamamatsu ultrafast high resolution cooled CCD camera operated by an Improvision software package OpenLab, which is capable of confocal imaging and 3-D rendering) .
- a Zeiss Axioplan 2 MOT equipped for fluorescence imaging
- a Nomarski/DIC microscope e.g., a phase contrast microscope
- a state of the art imaging system e.g., a Hamamatsu ultrafast high resolution cooled CCD camera operated by an Improvision software package OpenLab, which is capable of confocal imaging and 3-D rendering
- a terrestial sample e.g., a soil sample taken from forest soil (e.g., from a temperate climate or a tropical rain forest) , farmland, tundra, alpine soil or landfill, mixed with agar and placed in a growth chamber as described above, could be incubated in a moist soil environment taken from the original sampling site.
- the moisture level of the incubation environment could be increased, e.g., with the admixture of rainwater, if desired to achieve the appropriate level of diffusion of nutrients into the interior of the growth chamber.
- sampling sites would be surface environments in medical facilities or in "sick" buildings, where not only could novel organisms be isolated but contaminating organisms, new or old, identified.
- a culture of visible organisms or a swipe of an appropriately exposed surface would be placed in a growth chamber as described above.
- the growth chamber would then be placed in an unobtrusive site in the sampled environment so as to be exposed to airborne nutrients during the incubation period.
- a purified colony of a specific microorganism can be seeded into, e.g., 10 growth chambers, cultured in the natural environment and the resulting biomass extracted. At approximately 10 8 cells per chamber, this amount of material is sufficient for screening for bioactivity and validation.
- Further upscaling for the production of lead compounds can be carried out, e.g., by one of the following methods: (1) domestication, e.g., by selecting those that can now grow alone on artificial media, either with or without prior exposure of the culture to a mutagen; (2) cloning the genes for the biosynthetic pathway of the identified novel lead compound into a conventional host strain, such as E. coli or Streptomyces coelicolor; (3) co-culturing with a "helper” organism; or (4) propagating a colony of an uncultivable organism on artificial media from a sizeable inoculum.
- domestication e.g., by selecting those that can now grow alone on artificial media, either with or without prior exposure of the culture to a mutagen
- cloning the genes for the biosynthetic pathway of the identified novel lead compound into a conventional host strain, such as E. coli or Streptomyces coelicolor
- co-culturing with a "helper" organism or
- a "helper" organism is one that has been discovered, as described herein, as being capable of supporting the growth of certain organisms previously considered as “uncultivable” when the two are co-cultured on a standard rich medium in Petri dishes.
- the propagation method used to upscale the growth of an uncultivated isolate may be performed on artificial media, e.g., nutrient agar on a Petri dish, if the inoculum is made larger than a single cell.
- a colony of an "uncultivable" organism from an environmental sample may be grown in a diffusion chamber, or cultured on an artificial medium in the presence of a "helper” organism. The colony is incubated for a period of time allowing it to reach a sufficient size.
- this colony is removed and placed without further dispersal onto an artificial nutrient medium in a Petri dish with incubation to achieve growth of a colony on this medium.
- a sizable part of this new colony is then reinoculated onto a new artificial medium, repeating the inoculation step to propagate and upscale the growth of this uncultivated organism.
- Such propagation may produce sufficient amounts of growth-promoting substances, such as an autoinducer growth pheromone, enabling growth on artificial media.
- Intertidal marine sediment (near the Marine Science Center, Northeastern University, Nahant, Massachusetts, U.S.A.) was used as a source of microorganisms.
- the upper layer of the sandy sediment harbors a rich community of microorganisms, primarily aerobic organoheterotrophs, which reach densities of over 10 9 cells/g and are mostly uncultivated .
- the microorganisms are separated from sediment particles by vortexing, then serially diluted and mixed with warm agar made with seawater, and, finally, placed in a diffusion chamber. Referring to Fig.
- an exemplary diffusion growth chamber (10) for in si tu cultivation of environmental microorganisms according to the invention is formed by a stainless steel washer (12) (70 mm o.d., 33 mm i.d., 3 mm in thickness; Bruce Watkins Supply, Inc., Wilmington, NC) and two 0.03- ⁇ m pore-size polycarbonate membranes (14) (Osmonics, Inc., Westborough, MA).
- the membranes glued to the washer with Silicon Glue II (General Electric, Waterford, NY), enclose the inner space (16), which contains the mixture of test microorganisms and semi-solid (0.7%) agar.
- Containers with these chambers are incubated in a temperature-controlled aquarium with recirculating natural seawater adjusted to 16 °C.
- Fig. 2 shows representative colonies of marine sediment microorganisms (compound microscope view, DIC - scale bar, 100 ⁇ m) . Most of these (>99%) were microcolonies not visible to the naked eye.
- Addition of 0.01% casein increased the number of colonies in the chamber, and this supplement appeared superior to starch or marine broth tested at a variety of concentrations (0.001% to 3.7%). Therefore, 0.01% casein in 0.7% agar with seawater was used in further experiments.
- the heaviest sediment particles in the supernatant were allowed to settle, and the supernatant was subsampled (100 to 400 ⁇ l) to obtain 10 5 to 10 6 detached cells.
- the subsamples were serially diluted, mixed with warm (40°C) agar supplemented with 0.01% technical grade casein (Sigma Aldrich, St. Louis, MO), and inoculated into growth chambers. After one week of incubation, microbial colonies were counted under a compound microscope equipped for DIC at 400 to 1,000X. The number of cells in the inoculum was determined by epifluorescence microscopy after staining with DAPI.
- Petri dish macrocolonies made up 0.054 ⁇ 0.051% of the inoculum, in agreement with reports in the literature 15"17 . In the final analysis, there were about 300 times as many microorganisms producing sustainable growth in the chambers as in Petri dishes.
- Fig. 4a shows a dissecting microscope view of MSCl colonies against a dark field (scale bar length - 80 ⁇ m) .
- the bar is 80 ⁇ m in length.
- Fig. 4b is a compound microscope view (DIC) of a single MSCl colony (scale bar length - 3 ⁇ im) .
- Fig. 4c is a SEM view of a portion of a colony (scale bar length - 3 ⁇ m) .
- a colony of MSCl was isolated with the aid of a tungsten wire (75 ⁇ m shaft and ⁇ l ⁇ m at tip; FHC, Inc., Bowdoinham, ME, U.S.A.), washed from agar in QG Buffer (Qiagen, Valencia, CA, U.S.A.), incubated for 5 min, collected on 2.0- ⁇ m pore-size polycarbonate membranes and fixed in 2.5% EM grade glutaraldehyde.
- Lewinella persica are filamentous bacteria with long, multicellular, unbranched cells of peach color.
- MSCl differ from Lewinella persica and other Lewinella and Herpetosiphon in details of general colony morphology (see 24 ) .
- CFB Cytophaga- Flexibacter-Bacterioides
- the MSCl isolates produced colonies upon re-inoculation from chamber to chamber. It was important to examine the capability of this isolate to grow under artificial conditions. The tested strains did not generally show growth in liquid or solid artificial media (e.g., made with seawater, casein, soluble starch or marine broth) . When growth of microcolonies was occasionally observed, there was no growth upon re- inoculation of these same colonies to another Petri dish. At the same time, material taken from a Petri dish did produce colonies in a chamber. It appears that cells grown in a chamber were occasionally capable of undergoing a limited number of divisions in the artificial environment of a Petri dish.
- liquid or solid artificial media e.g., made with seawater, casein, soluble starch or marine broth
- MSC2 MSC2 grew well in Petri dishes that were contaminated with certain other microorganisms.
- Arcobacter ni trofigilis are motile, spiral curved rod-shaped bacteria, capable of nitrogen fixation and nitrate respiration, and incapable of metabolizing carbohydrates 27 .
- MSC2 are also curved rod-shaped bacteria and are observed to be motile.
- the genus Arcojacter is commonly found in marine sediments 21 , and related 16S rRNA sequences have recently been recovered from this environment 22 .
- FIG. 5 shows synergistic growth of MSCl and MSC2 on Petri dishes.
- colonies were collected with a tungsten wire from diffusion chambers, diluted in autoclaved seawater to approximately 100,000 (MSCl) and 10 (MSC2) cells/ml, correspondingly, mixed with warm (40°C) agar (0.7% final concentration) supplemented with 0.01% technical grade casein, and poured into Petri dishes (35 mm diameter, 2.5 ml volume).
- MSCl could be cultured in Petri dishes in co- culture with either one of the two other isolates, MSC4 and MSC5.
- the fact that co-occurrence transformed uncultivable microorganisms into cultivable ones on standard Petri dishes is suggestive of the nature of uncultivability for at least some environmental microbes. The observed growth synergy is unlikely to be based on trivial cross-feeding, since the medium used (technical grade casein) was rich in nutrients. It seems possible that most microorganisms may require specific signals that indicate the presence of a familiar environment, in addition to essential nutrients. For example, substances from neighboring species could serve as "growth pheromones.” Both inter- and intraspecies pheromones have been described in bacteria 28,29 .
- the methods of the invention have the potential to provide an important source of diverse organisms for the development and production of novel compounds, e.g., small molecules, enzymes and antibiotics, for pharmaceutical, agricultural, chemical and industrial markets.
- novel compounds e.g., small molecules, enzymes and antibiotics
- the methods described herein can be used, e.g., for the discovery of natural products with activity against diseases and conditions that afflict mammals, such as cancer, immunodeficiency virus infection, microbial infections (e.g., bacterial and fungal infections), lipid metabolism disorders, inflammation, diabetes and the like.
- Such natural products discovered according to the present method can serve as lead compounds in drug discovery programs.
- Such drug discovery programs predicated on the novel natural products obtained via the present invention can employ the logic and methods of classical medicinal chemistry, computer-aided "rational" drug design, combinatorial or parallel synthesis protocols, combinatorial or parallel assay protocols, or any possible amalgamation of these methods and approaches.
- Novel natural products identified by the methods of the invention, or compounds resulting from drug discovery programs based on their use as lead compounds may be formulated and used as pharmaceutical, agricultural or veterinary agents.
- the ability to detect the presence of novel natural products is central to the practice of the subject invention.
- assays, especially high throughput assays are carried out to detect organic molecules and the like that are produced as part of a de novo synthesis pathway.
- a candidate microorganism isolated as described herein is first screened for bioactivity.
- whole cells of a specific microorganism can be screened for antimicrobial activity, e.g., by replica plating from an agar surface containing colonies of novel microorganisms according to the invention and carrying out an agar overlay screen with a test microorganism. Then, the compound responsible for the observed bioactivity can be isolated and analyzed further.
- whole cells of a specific microorganism can also be screened for antimicrobial activity using the diffusion chamber as described above by, e.g., using a semi-solid medium, and where the cells grow primarily within agar and not on the surface.
- an environmental sample containing microbial cells is diluted so that the sample contains preferably 1-100 cultivable cells.
- This sample is mixed with a semi-solid medium containing a test strain, e.g., B. subtilis at a concentration of, e.g., 10 6 cells/ml, which is then placed in the diffusion chamber.
- the mixed sample is incubated to allow uncultivated cells to form colonies.
- the B. subtilis cells form uniform growth throughout the medium. Empty zones of no or little B . subtilis growth are present around colonies of uncultivables that produce antibiotics. These colonies are isolated and tested further.
- diffusion chambers can be withdrawn from the environment after uncultivated organisms have formed colonies. The chambers can be opened and overlaid with a layer of nutrient agar to deliver nutrients that will diffuse into the underlying layer. Growth of B . subtilis occurs throughout the medium, but not around the colonies of organisms producing the antibiotics. Therefore, colonies of uncultivable organisms that produce antimicrobials will inhibit growth of test strains, producing empty zones visible, for example, under a microscope.
- the high throughput processing and analysis of large libraries of test extracts or compounds may be automated, e.g., using automated/robotic systems.
- This automation can include, for instance, such activities as: 1) arraying and storage of libraries of extracts or compounds; and 2) screening subject extracts and compounds in biological and biochemical assays.
- the details of the specific methods utilized will vary from one embodiment to the next, but can be readily implemented by those skilled in the art.
- the subject extracts or compounds may be tested for activity in high throughput biochemical or biological assays adapted for automatic readouts.
- extracts may be screened for antimicrobial activity by using a panel of test organisms to be read for, e.g., optical density.
- the method can also employ established procedures for robotic capillary electrophoresis (CE) affinity assay or multi-well plate (e.g., 96 or 384) screening.
- CE robotic capillary electrophoresis
- the goal is to develop an automated method that is sensitive and rapid.
- the test extracts or compounds can be tested in biochemical assays, such as competitive binding assays or enzyme activity assays.
- biochemical assays such as competitive binding assays or enzyme activity assays.
- Novel bioactive compounds from organisms isolated according to the invention may be provided as pharmaceutically acceptable compositions, which comprise a therapeutically effective amount of one or more of the compounds described above, formulated together with one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may be used for testing or therapeutic purposes.
- compositions may be specially formulated for administration in solid or liquid form, suitable for, e.g., oral administration; parenteral administration, for example by subcutaneous, intramuscular or intravenous injection; topical application, for example, as a cream, ointment or spray applied to the skin; or intravaginally or intrarectally, for example, as a pessary, cream or foam.
- therapeutically effective compound means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired therapeutic effect.
- pharmaceutically acceptable carrier means a pharmaceutically acceptable material, composition or vehicle involved in carrying or transporting the subject agent from one organ or portion of the body, to another organ or portion of the body without negative effect.
- Formulations of pharmaceutical compositions described herein may conveniently be presented in unit dosage form and may be prepared by conventional methods well known in the art of pharmacy. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated and the particular mode of administration.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions described herein may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound (or derivative) employed, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
- ATCC is a depository affording permanence of the deposit and ready accessibility thereto by the public if a patent is granted. All restrictions on the availability to the public of the material so deposited will be irrevocably removed upon the granting of a patent. The material will be available during the pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 CFR 1.14 and 35 USC 122.
- the deposited material will be maintained with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposited microorganism, and in any case, for a period of at least thirty (30) years after the date of deposit or for the enforceable life of the patent, whichever period is longer.
- Applicants' assignee acknowledges its duty to replace the deposit should the depository be unable to furnish a sample when requested due to the condition of the deposit.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Mushroom Cultivation (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60227837T DE60227837D1 (en) | 2001-09-26 | 2002-09-13 | ISOLATION AND CULTIVATION OF MICRO-ORGANISMS FROM NATURAL ENVIRONMENTS AND ASSOCIATED DISCOVERY OF DRUGS |
DK02770520T DK1456401T3 (en) | 2001-09-26 | 2002-09-13 | Isolation and diving of microoranisms from natural environment and drug discovery based thereon |
EP02770520A EP1456401B1 (en) | 2001-09-26 | 2002-09-13 | Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon |
CA2461915A CA2461915C (en) | 2001-09-26 | 2002-09-13 | Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon |
AU2002335757A AU2002335757B2 (en) | 2001-09-26 | 2002-09-13 | Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon |
JP2003530805A JP4373783B2 (en) | 2001-09-26 | 2002-09-13 | Cultivation and isolation of microorganisms from the natural environment and drug discovery from them |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32505201P | 2001-09-26 | 2001-09-26 | |
US60/325,052 | 2001-09-26 | ||
US10/135,960 | 2002-05-01 | ||
US10/135,960 US20030059866A1 (en) | 2001-09-26 | 2002-05-01 | Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003027233A2 true WO2003027233A2 (en) | 2003-04-03 |
WO2003027233A3 WO2003027233A3 (en) | 2004-07-08 |
Family
ID=26833851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/029256 WO2003027233A2 (en) | 2001-09-26 | 2002-09-13 | Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon |
Country Status (9)
Country | Link |
---|---|
US (1) | US20030059866A1 (en) |
EP (1) | EP1456401B1 (en) |
JP (1) | JP4373783B2 (en) |
AT (1) | ATE402268T1 (en) |
AU (1) | AU2002335757B2 (en) |
CA (1) | CA2461915C (en) |
DE (1) | DE60227837D1 (en) |
DK (1) | DK1456401T3 (en) |
WO (1) | WO2003027233A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9249382B2 (en) * | 2001-09-26 | 2016-02-02 | Northeastern University | Devices and methods for the selective isolation of microorganisms |
US7494810B2 (en) * | 2002-02-08 | 2009-02-24 | Franhofer Usa Incorporated | Method for accessing microbial diversity |
US20080038767A1 (en) * | 2002-02-08 | 2008-02-14 | Athena Biotechnologies, Inc. | Method for accessing microbial diversity |
IL151660A0 (en) * | 2002-09-09 | 2003-04-10 | Univ Ben Gurion | Method for isolating and culturing unculturable microorganisms |
JP5166399B2 (en) * | 2006-04-04 | 2013-03-21 | ノースイースタン ユニバーシティ | Devices and methods for isolation and culture of microorganisms |
DK200801722A (en) | 2008-12-05 | 2010-06-06 | Unisensor As | Optical sectioning of a sample and detection of particles in a sample |
AU2010327159B2 (en) * | 2009-12-04 | 2013-10-10 | Unisensor A/S | System and method for time-related microscopy of biological organisms |
WO2011107102A1 (en) | 2010-03-04 | 2011-09-09 | Unisensor A/S | Flexible sample container |
WO2015161914A2 (en) * | 2014-04-22 | 2015-10-29 | Merck Patent Gmbh | Method for detecting micro-colonies growing on a membrane or an agarose medium of a sample and a sterility testing apparatus |
US11027145B2 (en) | 2017-12-15 | 2021-06-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Laser induced ballistic particle implantation technique |
CN115074289A (en) * | 2022-07-04 | 2022-09-20 | 浙江大学杭州国际科创中心 | Method for preparing culture medium for culturing new species of bacteria |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863532A (en) * | 1996-03-14 | 1999-01-26 | The Regents Of The University Of California | Compositions and methods comprising cytostatic protein kinase |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4271266A (en) * | 1974-06-10 | 1981-06-02 | The Upjohn Manufacturing Company | Process for preparing lincomycin |
US5985274A (en) * | 1985-04-02 | 1999-11-16 | Pharmacia & Upjohn Company | Antibiotic 10381A1 and process for the preparation of antibiotics 10381B |
US5837691A (en) * | 1988-08-03 | 1998-11-17 | Schering Corporation | Actinomadura vulgaris subsp vulgaris and antimicrobial complex and antimicrobial |
US5436000A (en) * | 1991-01-11 | 1995-07-25 | University Of Texas System | Flagella-less borrelia |
US5739019A (en) * | 1994-08-08 | 1998-04-14 | Walker; Harrell L. | Method of isolating and propagating microorganisms and viruses |
DE69532106T2 (en) * | 1994-09-16 | 2004-07-22 | Nihon Shokuhin Kako Co., Ltd. | Maltose Phospharylase, Trehalose Phophorylase, Plesiomonas Strain, and Preparation of Trehalose |
FR2730734B1 (en) * | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | NEW COMPOUNDS MANIFESTING PROPERTIES INHIBITORING FARNESYL TRANSFERASE AND MICROORGANISM OF THE GENUS CHRYSOSPORIUM LIKELY TO BE USED TO PREPARE THEM |
CA2170839A1 (en) * | 1995-03-01 | 1996-09-02 | Janet Macinnes | Bacterial preparations, method for producing same, and their use as vaccines |
US5807735A (en) * | 1995-03-29 | 1998-09-15 | Exxon Research And Engineering Company | Solvent-resistant microorganisms |
US6030779A (en) * | 1995-07-18 | 2000-02-29 | Diversa Corporation | Screening for novel bioactivities |
US5710039A (en) * | 1995-08-30 | 1998-01-20 | Nihon University (Educational Foundationn) | Porphyromonas gingivicanis strain ATCC 55562 |
US6001586A (en) * | 1996-03-29 | 1999-12-14 | Genencor International, Inc. | Compartmentalization method for screening microorganisms |
MY118003A (en) * | 1996-04-22 | 2004-08-30 | Toyota Motor Co Ltd | Microorganisms that decompose halogenated hydrocarbons and their use |
US6110712A (en) * | 1996-04-23 | 2000-08-29 | Bio-Polymer Research Co., Ltd. | Cellulose-producing bacteria |
JP3323746B2 (en) * | 1996-08-01 | 2002-09-09 | キヤノン株式会社 | Novel microorganisms, organic compound biodegradation method and environmental restoration method |
KR0180858B1 (en) * | 1996-09-19 | 1999-04-01 | 김경환 | Novel ice nucleation microorganism |
KR100211674B1 (en) * | 1997-02-25 | 1999-08-02 | 윤종용 | Novel microorganism which is resistant to hydrogen peroxide |
AU756507B2 (en) * | 1998-03-18 | 2003-01-16 | Ajinomoto Co., Inc. | L-glutamic acid-producing bacterium and method for producing L-glutamic acid |
US6323021B1 (en) * | 1999-01-15 | 2001-11-27 | Industrial Technology Research Institute | Mutant strain of penicillium citrinum and use thereof for preparation of compactin |
-
2002
- 2002-05-01 US US10/135,960 patent/US20030059866A1/en not_active Abandoned
- 2002-09-13 AT AT02770520T patent/ATE402268T1/en active
- 2002-09-13 WO PCT/US2002/029256 patent/WO2003027233A2/en active IP Right Grant
- 2002-09-13 DE DE60227837T patent/DE60227837D1/en not_active Expired - Lifetime
- 2002-09-13 AU AU2002335757A patent/AU2002335757B2/en not_active Expired
- 2002-09-13 DK DK02770520T patent/DK1456401T3/en active
- 2002-09-13 CA CA2461915A patent/CA2461915C/en not_active Expired - Lifetime
- 2002-09-13 JP JP2003530805A patent/JP4373783B2/en not_active Expired - Fee Related
- 2002-09-13 EP EP02770520A patent/EP1456401B1/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863532A (en) * | 1996-03-14 | 1999-01-26 | The Regents Of The University Of California | Compositions and methods comprising cytostatic protein kinase |
Non-Patent Citations (3)
Title |
---|
REN ET AL: 'Cloning and characterization of GEF-H1, a microtubule-associated guanine nucleotide exchange factor for Rac and Rho GTPases' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 273, no. 52, 25 December 1998, pages 34954 - 34960, XP002977040 * |
See also references of EP1456401A2 * |
WHITEHEAD ET AL.: 'Expression cloning of lfc, a novel oncogene with structural similarities to guanine nucleotide exchange factors and to the regulatory region of protein kinase C' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 270, no. 31, 04 August 1995, pages 18388 - 18395, XP002977039 * |
Also Published As
Publication number | Publication date |
---|---|
JP2005503171A (en) | 2005-02-03 |
DK1456401T3 (en) | 2008-10-20 |
CA2461915A1 (en) | 2003-04-03 |
AU2002335757B2 (en) | 2007-08-02 |
JP4373783B2 (en) | 2009-11-25 |
EP1456401A2 (en) | 2004-09-15 |
CA2461915C (en) | 2012-01-17 |
WO2003027233A3 (en) | 2004-07-08 |
ATE402268T1 (en) | 2008-08-15 |
DE60227837D1 (en) | 2008-09-04 |
US20030059866A1 (en) | 2003-03-27 |
EP1456401A4 (en) | 2005-11-16 |
EP1456401B1 (en) | 2008-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gurung et al. | Isolation and characterization of antibacterial actinomycetes from soil samples of Kalapatthar, Mount Everest Region | |
González et al. | Actinomycetes isolated from lichens: evaluation of their diversity and detection of biosynthetic gene sequences | |
Gunther IV et al. | The biofilm forming potential of bacterial species in the genus Campylobacter | |
US7011957B2 (en) | Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon | |
Bravo et al. | The long-term survival of Acinetobacter baumannii ATCC 19606 T under nutrient-deprived conditions does not require the entry into the viable but non-culturable state | |
WO2006029248A2 (en) | Hollow fiber technique for in vivo study of cell populations | |
CA2461915C (en) | Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon | |
Kumar et al. | An actinomycete isolate from solitary wasp mud nest having strong antibacterial activity and kills the Candida cells due to the shrinkage and the cytosolic loss | |
AU2002335757A1 (en) | Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon | |
Brookman et al. | Identification of spores in the polycentric anaerobic gut fungi which enhance their ability to survive | |
US9249382B2 (en) | Devices and methods for the selective isolation of microorganisms | |
Bishop et al. | Patterns of bacterial diversity in embryonic capsules of the spotted salamander Ambystoma maculatum: an expanding view of a symbiosis | |
Maya et al. | Cyanobacterial microbiotic crusts in eroded soils of a tropical dry forest in the Baja California Peninsula, Mexico | |
US20050130256A1 (en) | Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon | |
Al-Joubori et al. | The isolation of novel terrestrial Streptomyces strains with antimicrobial and cytotoxic properties | |
AU2007231767B8 (en) | Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon | |
EP1999248B1 (en) | Devices and methods for the isolation and cultivation of microorganisms | |
Hossain et al. | Aspergillus niger grows faster than Escherichia coli in eosin methylene blue media and deter their growth by reducing the pH of the media | |
Hadid et al. | PHENOTYPIC AND MOLECULAR IDENTIFICATION OF SOME SPECIES OF CANDIDA SPP. | |
Parmar et al. | Characterization and antagonistic potential of soil actinomycetes against pathogens of human mycosis | |
CH et al. | Isolation of Antibiotic Producing Microorganisms from Two Soil Samples of Phirangipuram, Guntur | |
Kaur | Isolation and Characterization of Uncultured Bacteria from Wheat Seeds, Soil and Sponge | |
Yeboah-Manu et al. | Primary Isolation of Mycobacterium ulcerans | |
Wibowo et al. | Antifungal Activity of Bacteria Associated Aplysina sp. Sponge Collected from Enggano Island, North Bengkulu, Indonesia Against Candida albicans | |
Richa et al. | SOIL AND PHARMACY: FORMATION OF ANTIBIOTICS VIA THE MICROBES OBTAINED THROUGH AGRICULTURAL SOILS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2461915 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002335757 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002770520 Country of ref document: EP Ref document number: 2003530805 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002770520 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002335757 Country of ref document: AU |